See more : Morgan Stanley Emerging Markets Debt Fund, Inc. (MSD) Income Statement Analysis – Financial Results
Complete financial analysis of PAVmed Inc. (PAVM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PAVmed Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Colonnade Acquisition Corp. II (CLAA-WT) Income Statement Analysis – Financial Results
- Qbic Technology Co., Ltd. (6825.TWO) Income Statement Analysis – Financial Results
- Federal Home Loan Mortgage Corporation (FMCCP) Income Statement Analysis – Financial Results
- Ameren Illinois Company PFD 4% (AILLP) Income Statement Analysis – Financial Results
- OUG Holdings Inc. (8041.T) Income Statement Analysis – Financial Results
PAVmed Inc. (PAVM)
About PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.45M | 377.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.42M | 3.61M | 585.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 0.00 | 0.00 |
| Gross Profit | -3.97M | -3.24M | -85.00K | -23.00K | -14.23K | -9.79K | -7.11K | -3.79K | 0.00 | 0.00 |
| Gross Profit Ratio | -161.83% | -858.62% | -17.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.28M | 25.55M | 19.85M | 10.96M | 6.63M | 4.25M | 2.62M | 1.72M | 489.33K | 22.29K |
| General & Administrative | 30.95M | 41.04M | 25.57M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 0.00 |
| Selling & Marketing | 17.58M | 19.32M | 8.90M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.53M | 60.36M | 34.46M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 400.00K |
| Other Expenses | 2.02M | 1.78M | 0.00 | 0.00 | -558.60K | -903.00K | -3.12M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 64.83M | 87.69M | 54.31M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Cost & Expenses | 71.25M | 91.30M | 54.89M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Interest Income | 505.00K | 1.27M | 0.00 | 53.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 589.00K | 1.27M | 0.00 | 53.00K | 32.67K | 2.39M | 724.68K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.93M | 2.55M | 226.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 1.78M | 422.29K |
| EBITDA | -75.74M | -99.41M | -55.90M | -35.81M | -16.67M | -12.07M | -11.15M | -5.65M | -1.78M | -126.48K |
| EBITDA Ratio | -3,088.99% | -24,615.92% | -10,833.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -68.80M | -90.93M | -54.39M | -23.35M | -14.30M | -10.56M | -8.03M | -5.65M | -1.78M | -422.29K |
| Operating Income Ratio | -2,805.67% | -24,118.57% | -10,878.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.47M | -12.15M | -1.73M | -12.54M | -2.97M | -7.61M | -1.49M | 0.00 | 0.00 | -126.48K |
| Income Before Tax | -79.26M | -103.24M | -56.13M | -35.89M | -17.27M | -18.17M | -9.52M | -5.65M | -1.78M | -548.77K |
| Income Before Tax Ratio | -3,232.59% | -27,384.08% | -11,225.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -5.78M | -1.56M | -1.34M | -204.07K | 878.87K | -1.00 | -1.78M | -126.48K |
| Net Income | -64.18M | -101.29M | -50.35M | -34.33M | -15.93M | -17.97M | -9.52M | -5.65M | -1.78M | -548.77K |
| Net Income Ratio | -2,617.25% | -26,868.44% | -10,069.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| EPS Diluted | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| Weighted Avg Shares Out | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
| Weighted Avg Shares Out (Dil) | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
Patent covers proprietary method using methylation of the CCNA1 gene to help detect esophageal precancer and cancer NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company,...
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care
Grant will fund research to optimize Veris Cancer Care Platform for medically underserved cancer patients, in partnership with an academic cancer center NEW YORK , Oct. 10, 2024 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage...
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will participate in the 2024 Maxim...
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024
Company to showcase EsoGuard® and EsoCheck® at the conference's Innovation Pavilion NEW YORK , Oct. 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...
American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test
Follows the Society's strong endorsement of EsoGuard medical policy coverage by payors NEW YORK , Sept. 24, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc....
PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements
Efforts include appointment of seasoned biotech investor Sundeep Agrawal, M.D. to board to replace departing directors NEW YORK , Sept.
Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress
Leading experts to discuss advances in technologies to prevent esophageal cancer through esophageal precancer screening NEW YORK , Sept. 10, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary...
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters NEW YORK , Sept. 3, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics...
Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer
Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq:...
PAVmed Inc. (PAVM) Q2 2024 Earnings Call Transcript
PAVmed Inc. (NASDAQ:PAVM ) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Matt Riley - Director of IR Lishan Aklog - Chairman and CEO Dennis McGrath - CFO Conference Call Participants Matthew Park - Cantor...
Source: https://incomestatements.info
Category: Stock Reports